In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus

• Published in: Microbiology spectrum 2022-02, Vol.10 (1), p.e0132121-e0132121
• Main Authors: Aragaw, Wassihun Wedajo, Cotroneo, Nicole, Stokes, Suzanne, Pucci, Michael, Critchley, Ian, Gengenbacher, Martin, Dick, Thomas
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Bacterial Proteins - genetics; Bacterial Proteins - metabolism; Benzimidazoles - pharmacology; DNA gyrase; DNA Gyrase - genetics; DNA Gyrase - metabolism; Drug Resistance, Bacterial; GyrB; Humans; MAB_4384; Microbial Sensitivity Tests; Mutation; Mycobacteriology; Mycobacterium abscessus - drug effects; Mycobacterium abscessus - enzymology; Mycobacterium abscessus - genetics; Mycobacterium abscessus - growth & development; Mycobacterium avium - drug effects; Mycobacterium avium - enzymology; Mycobacterium avium - genetics; Mycobacterium avium - growth & development; Mycobacterium Infections, Nontuberculous - microbiology; non-tuberculous mycobacteria; NTM; Research Article; SPR720; Topoisomerase II Inhibitors - pharmacology
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.01321-21

The aminobenzimidazole SPR719 targets DNA gyrase in Mycobacterium tuberculosis. The molecule acts as inhibitor of the enzyme's ATPase located on the Gyrase B subunit of the tetrameric Gyrase A B protein. SPR719 is also active against non-tuberculous mycobacteria (NTM) and recently entered clinical development for lung disease caused by these bacteria. Resistance against SPR719 in NTM has not been characterized. Here, we determined spontaneous resistance frequencies in single step resistance development studies, MICs of resistant strains, and resistance associated DNA sequence polymorphisms in two major NTM pathogens Mycobacterium avium and Mycobacterium abscessus. A low-frequency resistance (10 CFU) was associated with missense mutations in the ATPase domain of the Gyrase B subunit in both bacteria, consistent with inhibition of DNA gyrase as the mechanism of action of SPR719 against NTM. For M. abscessus, but not for M. avium, a second, high-frequency (10 CFU) resistance mechanism was observed. High-frequency SPR719 resistance was associated with frameshift mutations in the transcriptional repressor MAB_4384 previously shown to regulate expression of the drug efflux pump system MmpS5/MmpL5. Our results confirm DNA gyrase as target of SPR719 in NTM and reveal differential resistance development in the two NTM species, with M. abscessus displaying high-frequency indirect resistance possibly involving drug efflux. Clinical emergence of resistance to new antibiotics affects their utility. Characterization of resistance is a first step in the profiling of resistance properties of novel drug candidates. Here, we characterized resistance against SPR719, a drug candidate for the treatment of lung disease caused by non-tuberculous mycobacteria (NTM). The identified resistance associated mutations and the observed differential resistance behavior of the two characterized NTM species provide a basis for follow-up studies of resistance to further inform clinical development of SPR719.